SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a five-year collaboration with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia, to analyze genomic information across large patient samples. Under terms of the agreement, Peter Mac researchers will use Affymetrix GeneChip® microarray technology for translational research projects, beginning with studies on ovarian cancer and carcinoma of unknown primaries.
